Detalhe da pesquisa
1.
CALR mutation burden in essential thrombocythemia and disease outcome.
Blood
; 143(13): 1310-1314, 2024 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38252902
2.
Genome-wide association study identifies novel susceptibility loci for KIT D816V positive mastocytosis.
Am J Hum Genet
; 108(2): 284-294, 2021 02 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33421400
3.
Effect of age and treatment on predictive value of measurable residual disease: implications for clinical management of adult patients with acute myeloid leukemia.
Haematologica
; 109(1): 60-71, 2024 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37345475
4.
Validation and molecular integration of the RR6 model to predict survival after 6 months of therapy with ruxolitinib.
Haematologica
; 2024 May 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38813708
5.
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes.
Ann Hematol
; 103(2): 437-442, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38060001
6.
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.
Ann Hematol
; 2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38438627
7.
The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis.
Am J Hematol
; 99(1): 68-78, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37846894
8.
Disease correlates and clinical relevance of hereditary α-tryptasemia in patients with systemic mastocytosis.
J Allergy Clin Immunol
; 151(2): 485-493.e11, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36309122
9.
Management of polycythemia vera: A survey of treatment patterns in Italy.
Eur J Haematol
; 110(2): 161-167, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36319575
10.
A globally applicable "triple A" risk model for essential thrombocythemia based on Age, Absolute neutrophil count, and Absolute lymphocyte count.
Am J Hematol
; 98(12): 1829-1837, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37665758
11.
Clonal dynamics and copy number variants by single-cell analysis in leukemic evolution of myeloproliferative neoplasms.
Am J Hematol
; 98(10): 1520-1531, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37399248
12.
ENABLE: treatment combination including decitabine and venetoclax in acute myeloid leukemia secondary to myeloproliferative neoplasms.
Future Oncol
; 19(2): 103-111, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36651780
13.
Novel drivers and modifiers of MPL-dependent oncogenic transformation identified by deep mutational scanning.
Blood
; 135(4): 287-292, 2020 01 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-31697803
14.
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study.
Blood
; 135(5): 381-386, 2020 01 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-31869407
15.
Portosystemic shunt is an effective treatment for complications of portal hypertension in hepatic myeloid metaplasia and improves nutritional status.
Liver Int
; 42(2): 419-424, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34963020
16.
Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis.
Am J Hematol
; 97(7): 846-855, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35338671
17.
Classification and Personalized Prognosis in Myeloproliferative Neoplasms.
N Engl J Med
; 379(15): 1416-1430, 2018 10 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30304655
18.
Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low-, intermediate-1-, intermediate-2-, and high-risk myelofibrosis in JUMP, a Phase 3b, expanded-access study.
Hematol Oncol
; 39(4): 558-566, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34224180
19.
Cerebral venous thrombosis and myeloproliferative neoplasms: A three-center study of 74 consecutive cases.
Am J Hematol
; 96(12): 1580-1586, 2021 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34453762
20.
Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases.
Am J Hematol
; 96(7): 781-789, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33844862